Discovering Novel Drug Targets for CNS Edema by In Vitro Genetics
Award amount
$1,492,650Program and phase
SBIR · Phase IIAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PREDICTIVE BIOLOGY
- Proposal award date
- 2018-09-30
- Contract end date
- 2020-08-31
- UEI
- F1PNSXJZC269
- Solicitation number
- PA18-574
- Topic code
- NINDS
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Genetically diverse mouse cerebellar organoids for in vitro neurotoxicology
- Single Cell Aneugen Assay in Neural Progenitor Cells
- Novel Single Cell Assay to Identify Genes Underlying Developmental Neurotoxicity
- Discovering Novel Drug Targets for CNS Edema by In Vitro Genetics
- Novel Mechanisms and Targets for Major Depressive Disorder in Astrocytes
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Enhancing Healthcare Delivery and Patient Outcomes: Noninvasive Wireless Sensors to Improve Ventricular Shunt Monitoring, Reduce Imaging, and Alleviate the Burden on Providers, Patients, and Families
- Commercialization Readiness Pilot for Flow Acceleration for Stroke Thrombolysis (FAST) System
- 3D in vitro model of genetic and sporadic FTD: accelerating novel therapeutic development
- Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries
- Promoting tissue repair and functional recovery after spinal cord injury by targeting the microtubule regulatory protein Fidgetin-like 2: Supplement for Imaging System
Research funding history
14 SBIR/STTR records share this UEI (2007–2020). Reported award amounts total $7,478,355. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services